Mikaeli J, Bishehsari F, Montazeri G, Yaghoobi M, Malekzadeh R
Digestive Disease Research Centre (DDRC), Shariati Hospital, Tehran University of Medical sciences, Tehran, Iran.
Aliment Pharmacol Ther. 2004 Aug 15;20(4):431-6. doi: 10.1111/j.1365-2036.2004.02080.x.
Pneumatic dilatation is considered to be the first line therapy for achalasia, but long-term outcome studies are scarce and limited by their retrospective design. There is also no consensus on the optimal method for performing pneumatic dilation as regard to balloon diameter, amount and the rate inflation pressure.
To address these questions in a large long-term prospective study.
Over a period of 10 years 262 achalasia patients referred to our centre were enrolled. All patients underwent a pre-treatment clinical evaluation and were followed every 6 months. The first 62 patients (group A) underwent dilatation with initial use of a 35 mm balloon with inflation pressure of 10 psi in 10 seconds (s). In group B (200 patients) we initially used a 30 mm balloon with inflation pressure of 10 psi in 30 s. Dilatation was repeated with incrementally larger balloons (35 and 40 mm) in case of relapse. We used rigiflex balloon and maintained pressure for 60 s after inflation in both groups.
Three perforations occurred in group A whereas no perforation took place in Group B. The cumulative proportional remission rate with single dilatation in groups A and B decreased from 83 and 75% in 6 months to 60 and 57% after 30 months of therapy respectively, the differences did not reach statistical significance. In patients who had undergone further dilatations the probability of remaining in remission at 1 year after the first and the second dilatation was 38 and 88% in group A, 20 and 89% in group B respectively. The probability of remaining in remission for 2 years increased from 20% after the first dilatation to 70% after the second dilatation.
Graded pneumatic balloon dilatation with 30 mm diameter and slower rate of balloon inflation is an effective and safe initial method of therapy for achalasia. The duration of remission can be extended by repeated dilatation with larger size balloon.
气囊扩张术被认为是贲门失弛缓症的一线治疗方法,但长期疗效研究较少,且受回顾性研究设计的限制。关于气囊直径、充气量和充气压力的最佳气囊扩张方法也尚未达成共识。
通过一项大型长期前瞻性研究来解决这些问题。
在10年期间,招募了262例转诊至我们中心的贲门失弛缓症患者。所有患者均接受了治疗前的临床评估,并每6个月进行一次随访。前62例患者(A组)最初使用35毫米气囊,在10秒内充气至10磅力/平方英寸(psi)进行扩张。B组(200例患者)最初使用30毫米气囊,在30秒内充气至10 psi。如果复发,则使用逐渐增大的气囊(35毫米和40毫米)重复扩张。两组均使用 Rigiflex 气囊,充气后保持压力60秒。
A组发生3例穿孔,而B组未发生穿孔。A组和B组单次扩张后的累积缓解率分别从6个月时的83%和75%降至治疗30个月后的60%和57%,差异无统计学意义。在接受进一步扩张的患者中,A组第一次和第二次扩张后1年保持缓解的概率分别为38%和88%,B组分别为20%和89%。第一次扩张后2年保持缓解的概率从20%增加到第二次扩张后的70%。
直径30毫米、气囊充气速度较慢的分级气囊扩张术是贲门失弛缓症一种有效且安全的初始治疗方法。使用更大尺寸的气囊重复扩张可延长缓解期。